This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study
by Zacks Equity Research
Data from a mid-stage study show that treatment with Edgewise's experimental drug reduces levels of a biomarker related to skeletal muscle damage.
CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change EWTXPositive Net Change
biotechs medical
Merck Ends Development of Two Experimental Cancer Drugs
by Zacks Equity Research
MRK's decision to discontinue the development of two cancer drugs follows a series of setbacks in multiple late-stage studies.
MRKPositive Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
by Ekta Bagri
We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025.
SRPTPositive Net Change VYGRNo Net Change CRSPPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
GILD Obtains Positive CHMP Opinion for Liver Disease Drug
by Zacks Equity Research
The CHMP recommends the approval of Gilead's seladelpar in combination with ursodeoxycholic acid for the treatment of primary biliary cholangitis in adults.
GSKNegative Net Change GILDNegative Net Change MRUSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases
by Zacks Equity Research
RHHBY wins approval for prefilled syringe of ophthalmology drug Vabysmo for three retinal conditions that can cause blindness.
REGNPositive Net Change RHHBYPositive Net Change BMYPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
CHMP Endorses Merck's Kidney Cancer Drug for Two Indications
by Zacks Equity Research
The CHMP's opinion is based on positive results from two late-stage studies on MRK's Welireg in two indications associated with renal cell carcinoma.
MRKPositive Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce
by Zacks Equity Research
Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.
EDITPositive Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs crispr gene-editing gene-therapy medical pharmaceuticals
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
by Zacks Equity Research
AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.
ABBVPositive Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease
by Zacks Equity Research
The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.
JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs immuno-therapy medical pharmaceuticals
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408
by Zacks Equity Research
Krystal Biotech posts initial clinical updates on its two pipeline candidates, KB407 and KB408, which are being developed to treat rare respiratory diseases.
CTMXPositive Net Change SPRONegative Net Change KRYSNegative Net Change CSTLPositive Net Change
biotechs
Regeneron Down 15.5% Year to Date: How to Play the Stock?
by Ekta Bagri
REGN's lead drug, Eylea, faces a rapid decline in sales, which has impacted overall performance, even though Dupixent maintains momentum. We advise investors to wait and watch for now.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD
by Zacks Equity Research
Novo Nordisk's diabetes drug, Ozempic, receives positive CHMP opinion in the EU for expanded use in T2D and CKD patients.
NVOPositive Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday
by Zacks Equity Research
Shares of QTTB fall after its experimental autoimmune disease drug failed to meet the primary endpoint in a mid-stage study for eczema.
CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change QTTBPositive Net Change
biotechs medical
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
by Zacks Equity Research
Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate cancer.
BMYPositive Net Change PFEPositive Net Change GILDNegative Net Change CADLPositive Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals
by Zacks Equity Research
Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.
GSKNegative Net Change ANABPositive Net Change CSTLPositive Net Change IMCRPositive Net Change
biotechnology biotechs pharmaceuticals
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as both a combination and monotherapy.
AZNPositive Net Change NVOPositive Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?
by Kinjel Shah
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its sales and profits to improve.
SNYPositive Net Change GSKNegative Net Change MRNAPositive Net Change HLNNegative Net Change
biotechs
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study
by Zacks Equity Research
Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients.
ALNYPositive Net Change PFEPositive Net Change GILDNegative Net Change CRDFPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
by Zacks Equity Research
uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.
ALNYPositive Net Change PFEPositive Net Change GILDNegative Net Change QUREPositive Net Change
biotechnology biotechs dna-sequencing gene-editing gene-therapy medical pharmaceuticals
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
by Zacks Equity Research
It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news also continued to be in the spotlight.
GSKNegative Net Change INCYPositive Net Change BIOAPositive Net Change QUREPositive Net Change CRDFPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines
by Zacks Equity Research
Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone flu vaccines.
SNYPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Bristol Myers Stock Surges 36.5% in Six Months: Time to Buy or Sell?
by Ekta Bagri
Bristol Myers stock has witnessed a stupendous rally in the past six months. We believe there is more room for growth, and any dip in the share price can be used as a buying opportunity.
BMYPositive Net Change PFEPositive Net Change GILDNegative Net Change
biotechnology biotechs dividend-yield medical pharmaceuticals
ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip?
by Ekta Bagri
ADMA Biologics has performed phenomenally in 2024. Given its strong trajectory, we recommend investors use any dip in the stock price as a buying opportunity.
GRFSPositive Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Editas Stock Rises on Updated Data From SCD Study of Reni-Cel
by Zacks Equity Research
EDIT's stock gains on updated positive safety and efficacy data from the phase I/II/III RUBY study of its lead candidate, reni-cel, for severe SCD.
PFEPositive Net Change GILDNegative Net Change HALOPositive Net Change EDITPositive Net Change
biotechnology biotechs medical pharmaceuticals
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential
by Zacks Equity Research
Kodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications.
PFEPositive Net Change GILDNegative Net Change HALOPositive Net Change KODPositive Net Change
biotechnology biotechs medical pharmaceuticals